Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
PMID: 15328117
2004
Antimicrobial agents and chemotherapy
Abstract: The 3TC(r) RT substitutions rtV173L, rtL180M, and rtM204V were present at study entry, and the additional substitutions rtI169T and rtM250V emerged during ETV-3TC combination treatment.
Abstract: Viral rebound occurred after 76 weeks of therapy with ETV at 1.0 mg, with the emergence of rtT184G, rtI169T, and rtS202I substitutions within the preexisting 3TC(r) background.
HBV mutation literature information.
PMID: 
2004
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator